<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Atrioventricular nodal reentrant tachycardia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Atrioventricular nodal reentrant tachycardia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Atrioventricular nodal reentrant tachycardia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bradley P Knight, MD, FACC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark S Link, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 08, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Atrioventricular nodal reentrant tachycardia (AVNRT) is a regular supraventricular tachycardia (SVT) that results from the formation of a reentry circuit confined to the AV node and perinodal atrial tissue. Because of its abrupt onset and termination, AVNRT is categorized as a paroxysmal SVT (PSVT). As with the majority of SVTs, the QRS complex in AVNRT is usually narrow (ie, ≤120 milliseconds), reflecting normal ventricular activation through the His-Purkinje system. However, rate-related aberrant conduction during SVT or an underlying bundle branch block can result in a wide QRS complex tachycardia. (See  <a class="medical medical_review" href="/z/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation", section on 'Paroxysmal and incessant SVT'</a>.)</p><p>This topic will review the mechanisms, clinical manifestations, diagnosis, and the management of AVNRT. A detailed discussion of the broader approach to narrow QRS complex tachycardias is presented separately. (See  <a class="medical medical_review" href="/z/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation"</a>.)</p><p class="headingAnchor" id="H517939517"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>AVNRT is the most common form of regular, sustained, paroxysmal supraventricular tachycardia (PSVT), accounting for nearly two-thirds of all PSVTs, and is more common in women compared with men [<a href="#rid1">1-3</a>]. AVNRT can present at any age, but as with AV reentrant tachycardia (AVRT) that involves an accessory pathway, it is more likely to begin in young adults. In a series of 231 patients with AVNRT, the mean age of symptom onset was 32 years, with two-thirds of cases beginning after the age of 20 [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H517939555"><span class="h1">ANATOMY AND PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The physiologic substrate for AVNRT involves dual electrical pathways that lead to the compact AV node  (<a class="graphic graphic_table graphicRef53347" href="/z/d/graphic/53347.html" rel="external">table 1</a>) [<a href="#rid5">5,6</a>]. The arrhythmia usually develops in hearts that are otherwise normal, although it can also occur in the presence of underlying structural heart disease [<a href="#rid7">7,8</a>]. A more detailed discussion of the electrophysiology of AVNRT can be found in published reviews [<a href="#rid5">5,6,9,10</a>]. (See <a class="local">'Dual AV nodal physiology'</a> below.)</p><p class="headingAnchor" id="H517939817"><span class="h2">Anatomy</span><span class="headingEndMark"> — </span>The exact anatomic distribution of these pathways is uncertain. Koch's triangle is bounded by the tricuspid ring and the tendon of Todoro, which bracket the coronary sinus at the base of the triangle and are in close proximity forming the apex near the His bundle at the membranous septum  (<a class="graphic graphic_figure graphicRef69647" href="/z/d/graphic/69647.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef52196" href="/z/d/graphic/52196.html" rel="external">figure 2</a>) [<a href="#rid5">5,11</a>]. As an approximation, Koch's triangle can be divided into thirds:</p><p class="bulletIndent1"><span class="glyph">●</span>The anterior third, which contains the AV node and fast pathways</p><p class="bulletIndent1"><span class="glyph">●</span>The middle third</p><p class="bulletIndent1"><span class="glyph">●</span>The posterior third, the usual site of slow pathways</p><p></p><p class="headingAnchor" id="H517939999"><span class="h2">Dual AV nodal physiology</span><span class="headingEndMark"> — </span>The simplest concept of AV nodal physiology that allows for reentry involves separate electrical pathways proximal to the AV node  (<a class="graphic graphic_figure graphicRef79760" href="/z/d/graphic/79760.html" rel="external">figure 3</a>). This model is supported by clinical observations as well as animal and human mapping studies [<a href="#rid5">5,12,13</a>]. These pathways may be distinct anatomic structures, or they may be functionally separate (ie, regions that appear anatomically continuous but have different electrical properties). It is possible that some cases of AVNRT are acquired when there is right atrial pressure overload leading to changes in the electrophysiologic properties of the AV nodal inputs. Rare cases of familial AVNRT have also been reported [<a href="#rid14">14</a>]. Whether the dual pathways are anatomic or functional, in order for reentry to occur, they must have different conduction velocities and refractory periods [<a href="#rid15">15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>One pathway conducts rapidly and has a relatively long refractory period. This is called the <strong>fast pathway</strong>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The second pathway conducts relatively slowly and has a shorter refractory period. This is called the <strong>slow pathway</strong>.</p><p></p><p>The origins of the fast and slow pathways are probably in perinodal atrial tissue. These pathways join and enter a final common pathway in the compact AV node. While atrial tissue above the AV node appears to be part of the reentrant circuit, the bundle of His below the node is <strong>not</strong> a necessary part of the circuit. This can be illustrated by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>AVNRT is associated with 2:1 AV block in approximately 10 percent of patients [<a href="#rid16">16</a>]. The AV block in this setting is probably a functional infranodal block within the bundle of His [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>His bundle electrograms indicate that reentry is proximal to the recording site [<a href="#rid17">17,18</a>].</p><p></p><p>Not all patients with AVNRT have evidence of dual pathways during electrophysiology (EP) studies. Conversely, not all patients with dual AV nodal pathways have clinical AVNRT  (<a class="graphic graphic_waveform graphicRef60369 graphicRef72161" href="/z/d/graphic/60369.html" rel="external">waveform 1A-B</a>). The imperfect association between dual AV nodal physiology and clinical AVNRT was illustrated in a series of 180 patients undergoing EP studies for a variety of indications [<a href="#rid19">19</a>]. In the authors' experience, however, a vast majority of patients with documented AVNRT have clear evidence of dual AV nodal pathways with an inferior rightward slow pathway extension at the time of an EP procedure. A concealed atrio-Hisian tract that bypasses the AV node may constitute the retrograde fast pathway in up to a third of all apparently "typical" AVNRT cases [<a href="#rid20">20</a>]. Thus, the anatomic and electrophysiologic mechanism of AVNRT may be more complex than the dual AV nodal physiology model suggests [<a href="#rid21">21,22</a>].</p><p class="headingAnchor" id="H517940374"><span class="h3">Dual AV nodal pathways during normal sinus rhythm</span><span class="headingEndMark"> — </span>During normal sinus rhythm, AV conduction occurs as follows  (<a class="graphic graphic_figure graphicRef79760" href="/z/d/graphic/79760.html" rel="external">figure 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>The normal sinus beat enters the AV node and the impulse travels down both the fast and slow pathways.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The impulse traveling down the fast pathway reaches the His bundle first, creating a refractory wake.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The impulse traveling down the slow pathway is extinguished when, in the area of the final common pathway, it runs into the refractory wake of the impulse that had traveled down the fast pathway. The advent of ultrahigh-density three-dimensional mapping has made it possible to detect this site of collision during sinus rhythm in patients with dual AV nodal pathways [<a href="#rid23">23</a>].</p><p></p><p class="headingAnchor" id="H517941009"><span class="h2">Typical AVNRT</span><span class="headingEndMark"> — </span>Approximately 80 to 90 percent of patients with AVNRT present with what is called the common form of the arrhythmia. The common form is also called "typical AVNRT" or "slow-fast" AVNRT.</p><p>Typical AVNRT usually initiates as follows  (<a class="graphic graphic_figure graphicRef79760" href="/z/d/graphic/79760.html" rel="external">figure 3</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>A premature atrial complex (PAC; also referred to a premature atrial beat, premature supraventricular complex, or premature supraventricular beat) (or less commonly, a premature junctional or ventricular beat with retrograde conduction) arrives at the AV node when the fast pathway is in its refractory period. Thus, antegrade conduction down the fast pathway is blocked.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the premature beat arrives in a specific time window (ie, a "critically timed" premature beat), the slow pathway, with a shorter refractory period than the fast pathway, is available for conduction to the ventricle.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The premature beat conducts via the slow pathway, through the final common pathway, to the bundle of His. As a result, the PR interval of the premature beat will be longer than those of normal beats conducted through the fast pathway.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the fast pathway has recovered its excitability by the time the slow pathway impulse reaches the distal junction of the two pathways, the impulse can conduct retrograde up the fast pathway. The circuit may then become repetitive with antegrade conduction back down the slow pathway and retrograde conduction up the fast pathway resulting in a sustained tachycardia  (<a class="graphic graphic_figure graphicRef79760" href="/z/d/graphic/79760.html" rel="external">figure 3</a> and <a class="graphic graphic_figure graphicRef50122" href="/z/d/graphic/50122.html" rel="external">figure 4</a>).</p><p></p><p>This proposed mechanism explains a number of clinical observations in AVNRT:</p><p class="bulletIndent1"><span class="glyph">●</span>A single PAC (or retrograde penetration of the AV node from a junctional or premature ventricular complex/contraction [PVC; also referred to a premature ventricular beats or premature ventricular depolarizations]) can initiate the arrhythmia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Penetration of the reentrant circuit by a premature beat can abruptly terminate the arrhythmia.</p><p></p><p class="headingAnchor" id="H517941192"><span class="h2">Atypical AVNRT</span><span class="headingEndMark"> — </span>Up to 20 percent of patients with AVNRT have uncommon forms of the arrhythmia, referred to as "atypical AVNRT." As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Antegrade conduction can occur down the fast pathway with retrograde conduction up the slow pathway  (<a class="graphic graphic_figure graphicRef56806" href="/z/d/graphic/56806.html" rel="external">figure 5</a> and <a class="graphic graphic_figure graphicRef66828" href="/z/d/graphic/66828.html" rel="external">figure 6</a> and <a class="graphic graphic_waveform graphicRef81639" href="/z/d/graphic/81639.html" rel="external">waveform 2</a>) [<a href="#rid24">24</a>]. This is referred to as "fast-slow" AVNRT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients have multiple slow pathways, resulting in "slow-slow AVNRT" variants in which both the antegrade and retrograde limbs of the circuit utilize slow AV nodal pathways.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rarely during AVNRT, conduction through the reentrant circuit is so slow that the heart rate is less than 100 beats per minute, by definition not a tachycardia. Despite the absence of tachycardia, patients can be symptomatic and may be treated with a slow pathway ablation. This arrhythmia, sometimes referred to as AV nodal reentrant arrhythmia (AVNRA), has been mistaken for a junctional rhythm. (See  <a class="medical medical_review" href="/z/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation", section on 'Undetectable P waves'</a>.)</p><p></p><p>Typical and atypical AVNRT have rarely been found to coexist in the same patient during electrophysiology studies [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H4"><span class="h2">Symptoms</span><span class="headingEndMark"> — </span>Patients with AVNRT most commonly report palpitations, dizziness or lightheadedness, and dyspnea. Because of the paroxysmal nature of the arrhythmia, the onset and termination of the symptoms are usually sudden. Those with significant heart disease may have additional symptoms such as dyspnea and chest pain. Because atrial activation occurs coincident with ventricular activation during typical AVNRT, atrial contraction occurs when the tricuspid valve is closed, causing rhythmic abrupt rises in venous pressure, and can result in a sensation of neck pounding. Some patients with AVNRT have a feeling of polyuria and experience a diuresis during or after AVNRT; the mechanism probably is related to an elevated mean right atrial pressure and plasma level of atrial natriuretic peptide, which are present during the arrhythmia [<a href="#rid26">26</a>].</p><p>In a series of 167 supraventricular tachycardia (SVT) patients referred for radiofrequency ablation, the 64 patients with AVNRT reported the following symptoms [<a href="#rid27">27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Palpitations – 98 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Dizziness – 78 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Dyspnea – 47 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Chest pain – 38 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Fatigue – 19 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Syncope – 16 percent</p><p></p><p>Syncope is an uncommon feature of AVNRT and appears to be more likely with high heart rates (eg, heart rate ≥170 beats per minute). However, factors other than heart rate also contribute to syncope. As an example, abnormal vasomotor adaptation during AVNRT has been reported, suggesting a role for neurally mediated (neurocardiogenic) responses [<a href="#rid28">28,29</a>].</p><p>In very rare cases, AVNRT can result in cardiac arrest [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H583559382"><span class="h2">Triggers</span><span class="headingEndMark"> — </span>Most often there is no apparent precipitating cause for episodes of AVNRT.</p><p>In some patients, nicotine, alcohol, stimulants, and exercise can initiate episodes. A 2020 scientific statement from the American Heart Association details drugs associated with AVNRT [<a href="#rid31">31</a>].</p><p>Some patients experience the onset of AVNRT during sleep or after sudden bending forward or squatting, all of which can enhance vagal tone. In contrast to using vagal maneuvers to terminate AVNRT, increased vagal tone may facilitate the induction of AVNRT in some circumstances. In one series of 10 patients with AVNRT, electrophysiologic data were measured before and during continuous enhancement of vagal tone induced by infusing <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a> [<a href="#rid32">32</a>]. Vagal enhancement markedly prolonged the effective refractory period and functional refractory period of antegrade conduction in the fast pathway. However, the refractoriness of antegrade conduction in the slow pathway and retrograde conduction in the fast pathway were unchanged.</p><p class="headingAnchor" id="H16"><span class="h2">Electrocardiographic characteristics</span><span class="headingEndMark"> — </span>All patients with palpitations should undergo 12-lead electrocardiography (ECG), ideally while symptomatic. There are several ECG features that are helpful in confirming the diagnosis of AVNRT.</p><p class="bulletIndent1"><span class="glyph">●</span>Ventricular rate – The ventricular rate is generally between 120 and 220 beats per minute.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abrupt onset following PAC – If the initiation of the tachycardia is captured on a tracing, the tachycardia often begins with a PAC with sudden prolongation of the PR interval  (<a class="graphic graphic_figure graphicRef50122" href="/z/d/graphic/50122.html" rel="external">figure 4</a>). (See <a class="local">'Typical AVNRT'</a> above.) At times, a brief run of atrial tachycardia can initiate typical AVNRT with the last beat of the atrial tachycardia conducting over the slow pathway.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Relationship between QRS complexes and P waves – Because of the relationships between the QRS complex and the following P wave, typical AVNRT is referred to as a "short RP tachycardia," while atypical AVNRT is a "long RP tachycardia" [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation", section on 'RP relationship'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In typical AVNRT, retrograde atrial activation and antegrade ventricular activation occur almost simultaneously  (<a class="graphic graphic_figure graphicRef50122" href="/z/d/graphic/50122.html" rel="external">figure 4</a>). The P wave, therefore, is usually buried within or fused with the QRS complex.</p><p></p><p class="bulletIndent2">A component of the P wave is often evident slightly after, or less commonly before, the QRS  (<a class="graphic graphic_figure graphicRef54290" href="/z/d/graphic/54290.html" rel="external">figure 7</a> and <a class="graphic graphic_waveform graphicRef57001" href="/z/d/graphic/57001.html" rel="external">waveform 3</a>). When the P wave occurs shortly after the QRS complex, the fused waveform can produce a pseudo-R' (a second R wave) in lead V1 and a pseudo-S wave in the inferior leads. (See <a class="local">'Typical AVNRT'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In atypical AVNRT, retrograde atrial activation occurs long after ventricular activation, resulting in a P wave so late after the QRS complex that it appears to be occurring shortly before the next QRS complex  (<a class="graphic graphic_figure graphicRef56806" href="/z/d/graphic/56806.html" rel="external">figure 5</a> and <a class="graphic graphic_figure graphicRef66828" href="/z/d/graphic/66828.html" rel="external">figure 6</a> and <a class="graphic graphic_waveform graphicRef81639" href="/z/d/graphic/81639.html" rel="external">waveform 2</a>). This pattern resembles that seen in atrial tachycardias. In such cases, an electrophysiology (EP) study may be required to define the arrhythmogenic mechanism. (See <a class="local">'Atypical AVNRT'</a> above and  <a class="medical medical_review" href="/z/d/html/980.html" rel="external">"Invasive diagnostic cardiac electrophysiology studies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>P wave morphology – The P wave axis, when P waves can be clearly identified, is abnormal due to retrograde atrial activation. This is usually manifested on the electrocardiogram as a negative P wave axis with inverted P waves in leads II, III and aVF [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ST segment depression – Significant ST segment depression during tachycardia has been observed in 25 to 50 percent of patients with AVNRT, although it is more commonly seen in those with an AV reentrant tachycardia associated with an accessory pathway [<a href="#rid34">34-36</a>]. The ST segment depression does not represent myocardial ischemia in most patients (although it may in patients with significantly underlying coronary heart disease), but rather represents abnormalities of repolarization [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>T wave inversions following termination – After acute termination of AVNRT and other paroxysmal SVTs, T wave inversions may be seen in the anterior or inferior leads in approximately 40 percent of patients [<a href="#rid38">38</a>]. Inverted T waves may be seen immediately upon termination or may develop within the first six hours, and can persist for hours to days. The occurrence of negative T waves is not predicted by clinical parameters, tachycardia rate or duration, or the presence and extent of ST segment depression during the tachycardia. They are not the result of coronary artery disease, but are repolarization abnormalities, likely due to ionic current alterations resulting from the rapid rate.</p><p></p><p class="headingAnchor" id="H517942288"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of AVNRT should be suspected in a patient with the abrupt onset and offset of rapid sustained palpitations, often associated with lightheadedness or dyspnea. The ability for a patient to terminate the symptoms with a vagal maneuver is also suggestive of AVNRT as a potential etiology of symptoms. (See <a class="local">'Symptoms'</a> above and <a class="local">'Vagal maneuvers'</a> below.)</p><p>The diagnosis of AVNRT is typically confirmed following the review of an ECG acquired during the arrhythmia. When possible, review of the ECG at the onset or termination of the arrhythmia should be performed as this frequently provides additional information (ie, initiation following an PAC with sudden prolongation of the PR interval  (<a class="graphic graphic_figure graphicRef50122" href="/z/d/graphic/50122.html" rel="external">figure 4</a>)). When there is sudden termination of a regular paroxysmal supraventricular tachycardia (PSVT) that has 1:1AV conduction associated with AV block but not due to a PAC (last beat of the tachycardia is a P wave rather than a QRS complex that occurs at the expected timing), then an atrial tachycardia is very unlikely.</p><p class="bulletIndent1"><span class="glyph">●</span>In typical AVNRT, the P wave is usually buried within or fused with the QRS complex, resulting in a pseudo-R' (a second R wave) in lead V1 and a pseudo-S wave in the inferior leads.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In atypical AVNRT, the P wave occurs late after the QRS complex, often appearing shortly before the next QRS complex, resulting in a pattern that resembles atrial tachycardia.</p><p></p><p>If the diagnosis cannot be confirmed following review of the surface ECG, invasive electrophysiology studies can be performed in an effort to confirm the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/980.html" rel="external">"Invasive diagnostic cardiac electrophysiology studies"</a>.)</p><p class="headingAnchor" id="H517942295"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of palpitations is extensive  (<a class="graphic graphic_table graphicRef64306" href="/z/d/graphic/64306.html" rel="external">table 2</a>), and the etiology varies depending upon the population studied. The approach to palpitations is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6835.html" rel="external">"Evaluation of palpitations in adults"</a>.)</p><p>Once a tachycardia with a narrow QRS complex has been identified, the differential diagnosis is generally limited to SVTs, although on rare occasions idiopathic left ventricular tachycardia (a ventricular tachycardia arising from septum) can present as a narrow complex tachycardia. (See  <a class="medical medical_review" href="/z/d/html/965.html" rel="external">"Ventricular tachycardia in the absence of apparent structural heart disease", section on 'Idiopathic left ventricular tachycardia'</a>.)</p><p>Sustained narrow QRS complex tachycardias are generally divided according to whether the QRS complexes occur regularly or irregularly:</p><p class="bulletIndent1"><span class="glyph">●</span>Irregular QRS complexes – Atrial fibrillation, atrial flutter with variable conduction, multifocal atrial tachycardia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Regular QRS complexes – Sinus tachycardia, atrial flutter, AVNRT, atrioventricular reentrant tachycardia (AVRT), atrial tachycardia, and junctional ectopic tachycardia (JET). The term PSVT generally refers to AVNRT, AVRT, atrial tachycardia, and JET.</p><p></p><p>Because AVNRT is a regular tachycardia, the tachycardias with irregular QRS complexes can be excluded immediately. The remainder of the differential diagnosis discussion will focus on the other regular narrow QRS complex tachycardias.</p><p class="headingAnchor" id="H583559256"><span class="h2">Sinus tachycardia</span><span class="headingEndMark"> — </span>Sinus tachycardia is the most common narrow QRS complex tachycardia. Typically, sinus tachycardia is a response to another condition in which catecholamine release is physiologically enhanced or, less commonly, the parasympathetic nervous system withdrawn. In contrast to the abrupt onset and termination of AVNRT, sinus tachycardia has a gradual onset and offset, which typically occurs over 30 seconds to several minutes. Additionally, for the vast majority of patients, sinus tachycardia does not result in symptoms. (See  <a class="medical medical_review" href="/z/d/html/1074.html" rel="external">"Sinus tachycardia: Evaluation and management"</a>.)</p><p class="headingAnchor" id="H583559263"><span class="h2">Atrioventricular reentrant tachycardia</span><span class="headingEndMark"> — </span>Patients with AVRT can present in a similar fashion to patients with AVNRT. Both arrhythmias are associated with the abrupt onset of palpitations, and the surface ECG may appear very similar with regular QRS complexes and inverted P waves and a short RP interval that is less than one-half of the RR interval. AVNRT is most easily distinguished from AVRT when evidence of pre-excitation (short PR interval and delta wave) can be identified on prior ECGs during normal sinus rhythm (when available) consistent with an accessory pathway and the potential for AVRT. In the event of concealed pre-excitation, invasive electrophysiology studies may be required to distinguish AVNRT from AVRT. (See  <a class="medical medical_review" href="/z/d/html/976.html" rel="external">"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway"</a>.)</p><p class="headingAnchor" id="H583559270"><span class="h2">Atrial tachycardia</span><span class="headingEndMark"> — </span>As with AVNRT and AVRT, most patients with focal atrial tachycardia report an abrupt onset of palpitations associated with their episodes of tachycardia. In contrast to AVNRT, the P wave morphology during atrial tachycardia can appear normal or abnormal, depending upon the site of origin of the tachycardia, and the P waves tend to occur prior to the QRS complex, resulting in a long RP tachycardia. (See  <a class="medical medical_review" href="/z/d/html/900.html" rel="external">"Focal atrial tachycardia"</a>.)</p><p class="headingAnchor" id="H3606594098"><span class="h2">Junctional ectopic tachycardia</span><span class="headingEndMark"> — </span>Junctional ectopic tachycardia (JET) is a focal ectopic arrhythmia arising from the AV node region itself. It is a rare arrhythmia most often seen in young children as a congenital arrhythmia or after surgery for congenital heart disease [<a href="#rid39">39</a>]. JET can be difficult to differentiate from typical AVNRT. However, JET should be suspected when there is ventriculoatrial block during tachycardia and when the tachycardia is initiated by a premature junctional beat. Because the substrate related to JET is near the compact AV node, there is a greater concern for AV block during catheter ablation of JET compared with AVNRT [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H513740615"><span class="h2">Dual AV nodal nonreentrant tachycardia (DAVNNT)</span><span class="headingEndMark"> — </span>Patients with dual AV nodal pathways can rarely develop dual AV nodal nonreentrant tachycardia (DAVNNT) during sinus rhythm. This tachycardia occurs when each sinus beat is followed by two ventricular depolarizations due to consecutive double antegrade conduction via the fast and slow pathways and is usually is associated with alternating RR intervals [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H583559277"><span class="h2">Other SVTs</span><span class="headingEndMark"> — </span>Other than sinus tachycardia, AVRT, and atrial tachycardia, the remaining SVTs occur far less commonly. Inappropriate sinus tachycardia and sinoatrial nodal reentrant tachycardia have an identical appearance to sinus tachycardia. In contrast to sinus tachycardia, sinoatrial nodal reentrant tachycardia can have an abrupt onset (making it look identical to atrial tachycardia) and requires invasive electrophysiology studies to diagnose. Inappropriate sinus tachycardia tends to persist for days to weeks without the typical associations seen with sinus tachycardia (eg, pain, fever, hypovolemia, etc) and is relatively refractory to rate-slowing medications. Intraatrial tachycardia is a type of reentrant tachycardia seen almost exclusively in patients with underlying structural heart disease and prior cardiac procedures resulting in scar formation (eg, repair of congenital heart disease, catheter ablation for atrial fibrillation, etc). (See  <a class="medical medical_review" href="/z/d/html/1074.html" rel="external">"Sinus tachycardia: Evaluation and management", section on 'Inappropriate sinus tachycardia'</a> and  <a class="medical medical_review" href="/z/d/html/918.html" rel="external">"Sinoatrial nodal reentrant tachycardia (SANRT)"</a> and  <a class="medical medical_review" href="/z/d/html/937.html" rel="external">"Intraatrial reentrant tachycardia"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">INITIAL MANAGEMENT</span><span class="headingEndMark"> — </span>The initial management of a patient presenting with a narrow QRS tachycardia and suspected AVNRT is guided by whether or not the patient is experiencing signs and symptoms of hemodynamic instability  (<a class="graphic graphic_algorithm graphicRef126471" href="/z/d/graphic/126471.html" rel="external">algorithm 1</a>) related to the rapid heart rate (eg, hypotension, shortness of breath, chest pain suggestive of coronary ischemia, shock, and/or decreased level of consciousness). Unstable patients require urgent electrical cardioversion. However, it is very rare that a patient with paroxysmal supraventricular tachycardia (PSVT) requires electrical cardioversion.</p><p>There are several effective therapies for the acute termination of AVNRT, but few data regarding the optimal sequence of therapies for the acute termination of AVNRT [<a href="#rid42">42,43</a>]. These treatment options include:</p><p class="bulletIndent1"><span class="glyph">●</span>Vagal maneuvers (see  <a class="medical medical_review" href="/z/d/html/1034.html" rel="external">"Vagal maneuvers"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous (IV) <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a></p><p class="bulletIndent1"><span class="glyph">●</span>IV calcium channel blockers or beta blockers</p><p></p><p>Management recommendations are based upon an understanding of the properties and risks of the treatment options. Almost all patients, including those who are severely symptomatic, can be treated first with several attempts at vagal maneuvers or IV <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> [<a href="#rid42">42,43</a>]. Our recommendations are in general agreement with published professional society recommendations [<a href="#rid42">42,43</a>].</p><p class="headingAnchor" id="H3188937657"><span class="h2">Electrical cardioversion</span><span class="headingEndMark"> — </span>AVNRT almost always terminates with vagal maneuvers, spontaneously, or with intravenous antiarrhythmic therapy using <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a>, calcium channel blockers, or beta blockers. Very rarely, the patient is hemodynamically unstable or AVNRT persists in spite of vagal maneuvers and AV nodal blocking medications and electrical cardioversion should be considered  (<a class="graphic graphic_algorithm graphicRef126471" href="/z/d/graphic/126471.html" rel="external">algorithm 1</a>). Electrical cardioversion is usually successful but may require relatively high energy levels, probably due to the deep location of the reentrant pathway. If sinus rhythm is not restored following an initial 50 to 100 joule shock, subsequent shocks should be at higher energy levels  (<a class="graphic graphic_algorithm graphicRef130747" href="/z/d/graphic/130747.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/z/d/html/983.html" rel="external">"Cardioversion for specific arrhythmias"</a>.)</p><p class="headingAnchor" id="H583559782"><span class="h2">Vagal maneuvers</span><span class="headingEndMark"> — </span>Vagal maneuvers (eg, Valsalva maneuver or carotid sinus massage) are safe, easily performed, and effective first-line therapies for patients with AVNRT  (<a class="graphic graphic_algorithm graphicRef126471" href="/z/d/graphic/126471.html" rel="external">algorithm 1</a>). For patients who are hemodynamically stable and able to effectively perform the vagal maneuvers, we recommend at least one or two attempts at a standard Valsalva maneuver, followed by at least one or two attempts using the modified Valsalva maneuver (if AVNRT persists), as the initial treatment for AVNRT rather than another vagal maneuver or <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a>.</p><p>Vagal maneuvers increase parasympathetic tone, which produces a gradual slowing of conduction in the antegrade slow pathway. Slowing and eventual block in the antegrade slow pathway are the usual cause for arrhythmia termination with these interventions [<a href="#rid44">44</a>], although they can also produce abrupt block in the retrograde fast pathway. In one systematic review, which included 316 patients with a total of 965 episodes of supraventricular tachycardia (SVT; which included both AVNRT and atrioventricular reciprocating tachycardia), the standard Valsalva maneuver (exhaling forcefully against a closed glottis for 10 to 15 seconds) successfully terminated 45 percent of SVT episodes and was more successful than carotid sinus massage [<a href="#rid45">45</a>].</p><p>To perform a standard Valsalva maneuver, the patient is placed in a supine or semi-recumbent position and instructed inhale normally and then to exhale forcefully against a closed glottis for 10 to 15 seconds. A modified Valsalva maneuver (which begins with the standard Valsalva maneuver and is followed by supine positioning and passive leg raising) has been proposed as an improvement on the standard Valsalva maneuver. In the largest randomized trial of vagal maneuvers for the treatment of SVT, 428 patients with hemodynamically stable SVT were randomly assigned to perform the standard Valsalva maneuver (strain generating 40 mmHg pressure for 15 seconds while in a semi-recumbent position) or to perform the standard Valsalva maneuver followed by supine repositioning (placing the patient supine from the upright or semi-recumbent position) and passive leg raise for 15 seconds (214 patients per group) [<a href="#rid46">46</a>]. Patients performing the modified Valsalva maneuver with supine repositioning and passive leg raise were significantly more likely to have restoration of sinus rhythm at one minute (43 versus 17 percent in the standard Valsalva group; adjusted odds ratio 3.7; 95% CI 2.3-5.8). When feasible, we recommend the modified Valsalva maneuver given the greater likelihood of successful restoration of sinus rhythm.</p><p>Additional information on the performance and use of vagal maneuvers is presented separately. (See  <a class="medical medical_review" href="/z/d/html/1034.html" rel="external">"Vagal maneuvers"</a>.)</p><p class="headingAnchor" id="H583559788"><span class="h2">Adenosine</span><span class="headingEndMark"> — </span>If vagal maneuvers cannot be performed or if they fail to terminate the arrhythmia, IV medical therapy that blocks AV nodal conduction is indicated as the next step  (<a class="graphic graphic_algorithm graphicRef126471" href="/z/d/graphic/126471.html" rel="external">algorithm 1</a>). For patients with AVNRT that persists following vagal maneuvers (or in whom vagal maneuvers cannot be adequately performed), we recommend IV <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> rather than a calcium channel blocker or a beta blocker. The protocol for administration of adenosine is described in the algorithm  (<a class="graphic graphic_algorithm graphicRef141417" href="/z/d/graphic/141417.html" rel="external">algorithm 3</a>).</p><p>The advantages of <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> over other agents include rapid onset and a short half-life. Adenosine terminates AVNRT in over 80 percent of cases [<a href="#rid47">47-49</a>]. It is well tolerated in most patients, with the exception of those with severe bronchospastic asthma or severe coronary artery disease.</p><p>The use of <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> for the evaluation and termination of SVTs is presented separately. (See  <a class="medical medical_review" href="/z/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation", section on 'Intravenous adenosine'</a>.)</p><p class="headingAnchor" id="H583559794"><span class="h2">Other AV nodal blocking drugs</span><span class="headingEndMark"> — </span>If vagal maneuvers and <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> have been ineffective or terminate the tachycardia but are followed by an immediate recurrence, IV nondihydropyridine calcium channel blockers (eg, <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> and <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>) or IV beta blockers (eg, <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a>, <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">esmolol</a>) can be used  (<a class="graphic graphic_algorithm graphicRef126471" href="/z/d/graphic/126471.html" rel="external">algorithm 1</a>) to terminate AVNRT and prevent an immediate recurrence [<a href="#rid50">50,51</a>]. Clinical trials of an intranasally administered calcium channel blocker, etripamil, have shown it to be effective, with termination of SVT in up to 95 percent of patients [<a href="#rid52">52,53</a>]</p><p>The choice between these drugs is usually based on familiarity with and availability of the particular agents, although a calcium channel blocker would be preferred for a patient with reactive airway disease and active wheezing. Calcium channel and beta blockers are generally well tolerated, although potential adverse effects include hypotension (due to both negative inotropic and vasodilatory effects) and bradycardia [<a href="#rid54">54-56</a>]. Initial IV dosing options include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">Verapamil</a> – 5 to 10 mg IV bolus over two minutes; if no response, an additional 10 mg IV bolus may be administered 15 to 30 minutes following the initial dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">Diltiazem</a> – 0.25 mg/kg (average dose 20 mg) IV bolus over two minutes; if no response, an additional 0.35 mg/kg (average dose 25 mg) IV bolus may be administered 15 to 30 minutes following the initial dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">Metoprolol</a> – 2.5 to 5 mg IV bolus over two to five minutes; if no response, an additional 2.5 to 5 mg IV bolus may be administered every 10 minutes to a total dose of 15 mg.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">Esmolol</a> – 500 mcg/kg IV bolus over one minute, followed by a 50 to 150 mcg/kg/minute infusion, if necessary. Infusion rate can be adjusted as needed to maintain desired heart rate (up to 300 mcg/kg/minute).</p><p></p><p>Because of their longer half-lives, <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>, <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>, and beta blockers have the potential to suppress arrhythmia recurrence. Thus, these drugs should be used in patients who have early arrhythmia recurrence after termination with <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a>.</p><p class="headingAnchor" id="H583559826"><span class="h1">SUBSEQUENT MANAGEMENT</span><span class="headingEndMark"> — </span>The approach to the management of subsequent AVNRT episodes is based around acute management of recurrent episodes and/or preventive therapy to reduce or eliminate recurrences. Because AVNRT is usually well tolerated in the majority of patients, with a variety of safe and effective treatment options, and there are no compelling data favoring one therapy over another, the choice of long-term management strategies is largely influenced by patient preference. When working with a patient to select a treatment strategy, the following issues should be considered:</p><p class="bulletIndent1"><span class="glyph">●</span>Frequency of episodes</p><p class="bulletIndent1"><span class="glyph">●</span>Severity of symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Comorbid conditions</p><p class="bulletIndent1"><span class="glyph">●</span>Medication compliance</p><p class="bulletIndent1"><span class="glyph">●</span>Medication side effects</p><p></p><p>Patients who have had syncope in the setting of AVNRT may be subject to driving restrictions, which vary between municipalities. (See  <a class="medical medical_review" href="/z/d/html/1032.html" rel="external">"Syncope in adults: Management and prognosis", section on 'Driving restrictions'</a>.)</p><p class="headingAnchor" id="H843395555"><span class="h2">Acute management of recurrent episodes</span><span class="headingEndMark"> — </span>For the initial management of recurrent AVNRT, we generally work with the patient to develop a patient-directed treatment approach using either vagal maneuvers or an oral medication ("pill-in-the-pocket" approach). For most patients, we suggest a combination of one or more vagal maneuvers rather than the pill-in-the-pocket approach.</p><p>Patients who have experienced prior episodes and who have been educated on the proper performance of vagal maneuvers are frequently able to terminate subsequent episodes by performing vagal maneuvers on their own. If one or more vagal maneuvers successfully terminate the arrhythmia, patients generally do not need to seek urgent medical attention. Conversely, patients should be instructed to consult with their clinician or seek medical attention if the arrhythmia persists in spite of several attempts at patient-directed vagal maneuvers. (See <a class="local">'Vagal maneuvers'</a> above.)</p><p>An alternative patient-directed approach to the management of recurrent AVNRT is the pill-in-the-pocket approach. For selected patients with infrequent, well-tolerated, and long-lasting episodes of AVNRT, a single dose of an antiarrhythmic agent that was previously evaluated under observation can be effective for acute termination of the arrhythmia [<a href="#rid42">42,57,58</a>]. This strategy can both reduce the need for emergency department visits and avoid chronic medical therapy or invasive procedures. This approach has been evaluated with the nondihydropyridine calcium channel blockers, beta blockers, and the class IC antiarrhythmic drug <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a> [<a href="#rid58">58</a>]. However, based upon the efficacy of alternative, lower-risk therapies, and the efficacy of catheter ablation, flecainide is rarely used in the management of AVNRT. The choice of a particular agent will vary from patient to patient depending on comorbidities and patient preference.</p><p class="headingAnchor" id="H26"><span class="h2">Preventive therapy</span><span class="headingEndMark"> — </span>The decision to treat with long-term preventive therapy is based upon the following factors:</p><p class="bulletIndent1"><span class="glyph">●</span>The frequency of the arrhythmia</p><p class="bulletIndent1"><span class="glyph">●</span>The severity of the symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Patient tolerance of medications</p><p class="bulletIndent1"><span class="glyph">●</span>Patient preference</p><p></p><p>Many patients with infrequent episodes of AVNRT, or those with minimal or well-tolerated symptoms, may prefer a more conservative management approach with either no specific therapy or pharmacologic suppression. If pharmacologic therapy fails or if the side effects result from chronic medical therapy, catheter ablation remains an option. Conversely, for patients with significant symptoms, or for patients who prefer definitive therapy, even for rare, well-tolerated episodes, catheter ablation may be considered early in the patient's management [<a href="#rid42">42,43</a>].</p><p class="headingAnchor" id="H27"><span class="h3">No treatment</span><span class="headingEndMark"> — </span>Patients with infrequent and well-tolerated episodes of AVNRT may choose no chronic therapy. For these patients, we emphasize the patient-directed approach to the termination of recurrent episodes using one or more vagal maneuvers, with the ability to reassess long-term management options at any time should there be a change in the frequency or severity of recurrences. (See <a class="local">'Acute management of recurrent episodes'</a> above and  <a class="medical medical_review" href="/z/d/html/1034.html" rel="external">"Vagal maneuvers"</a>.)</p><p class="headingAnchor" id="H843396139"><span class="h3">Catheter ablation</span><span class="headingEndMark"> — </span>For patients with episodes of AVNRT that are either frequently occurring, refractory to medical therapy, poorly tolerated (eg, associated with near-syncope or syncope, angina, or severe dyspnea), or result in presentation to the emergency department or admission to the hospital, we recommend catheter ablation rather than chronic medical therapy as initial long-term management strategy. In such cases, the risks associated with recurrent arrhythmic events (eg, syncope with associated trauma) outweigh the procedural risks. In addition, the potential for definitive therapy makes ablation preferable to medical therapy in this setting.</p><p>Catheter ablation offers the opportunity for definitive cure of AVNRT in greater than 95 percent of patients, with high rates of success in both the typical and atypical forms [<a href="#rid59">59-61</a>]. However, ablation is associated with a small but non-trivial rate of procedural complications. The most significant potential complication of radiofrequency ablation for AVNRT is AV block (approximately 1 percent). Historically, the risk of AV block requiring permanent pacing following ablation ranged from 1 to 3 percent, but in multiple contemporary cohorts involving experienced electrophysiologists, the need for permanent pacing following the procedure has consistently been &lt;1 percent [<a href="#rid60">60,62,63</a>]. Older age and baseline PR interval prolongation are predictors of an increased risk of post-ablation AV block [<a href="#rid64">64-67</a>]. However, due to its high success rate in curing AVNRT by successful slow pathway ablation and low complication rate, catheter ablation is increasingly favored among patients with recurrent AVNRT [<a href="#rid42">42,43</a>]. (See  <a class="medical medical_review" href="/z/d/html/1007.html" rel="external">"Overview of catheter ablation of cardiac arrhythmias", section on 'Complications'</a>.)</p><p>The general approach to the catheter ablation of AVNRT is based upon the concept of dual AV nodal pathways. The most common AVNRT circuit (80 to 90 percent) involves antegrade conduction down the slow pathway and retrograde conduction up the fast pathway. The ablation target is the posterior slow pathway  (<a class="graphic graphic_figure graphicRef62108" href="/z/d/graphic/62108.html" rel="external">figure 8</a>) since ablation here carries the lowest risk of AV block, preserves fast pathway function (and a normal PR interval post-ablation), and is facilitated by reliable anatomic and electrophysiologic landmarks. The anterior fast pathway can also be ablated, but this approach is now limited to a few special circumstances since fast pathway ablation results in a long PR interval during sinus rhythm and is associated with a higher risk of heart block. During ablation for atypical "fast-slow" AVNRT, the slow pathway is the usual target. The slow pathway in these patients tends to be posteriorly located near the coronary sinus ostium as with patients who have typical AVNRT. However, there are reports of rare cases of atypical AV nodal reentry where the slow retrograde limb of the circuit is located more superiorly near the compact AV node [<a href="#rid68">68</a>]. The slow AV nodal pathway in patients with AVNRT can rarely be a leftward rather than rightward inferior AV nodal extension requiring ablation from the left atrial septum or within the coronary sinus [<a href="#rid69">69</a>].</p><p>The relative efficacy and costs of catheter ablation and medical therapy were compared in a series of 79 patients with newly documented supraventricular tachycardia (SVT) who were treated with either ablation or pharmacologic therapy, based upon patient preference [<a href="#rid70">70</a>]. After a follow-up period of 12 months, both medication and ablation decreased the frequency of arrhythmia-related symptoms, but ablation was more likely to result in complete abolition of symptoms (74 versus 33 percent). (See <a class="local">'Chronic suppressive therapy'</a> below.)</p><p class="headingAnchor" id="H28"><span class="h3">Chronic suppressive therapy</span><span class="headingEndMark"> — </span>For patients with symptomatic episodes of AVNRT who are not candidates for or who have declined catheter ablation, chronic medical therapy using beta blockers, nondihydropyridine calcium channel blockers, or antiarrhythmic drugs can be initiated in an effort to suppress recurrent arrhythmias.</p><p>There are few data comparing the relative efficacy of various agents used for chronic suppressive therapy of AVNRT. Because they are effective and well tolerated, the medications that are most commonly used for the chronic suppression of AVNRT are beta blockers (eg, <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a>) and nondihydropyridine calcium channel blockers (eg, <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> and <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>). Traditionally, beta blockers were preferred rather than calcium channel blockers unless the patient has reactive airway disease or another contraindication, although calcium channel blockers may have fewer side effects. The choice of a starting dose for chronic suppressive medication will vary depending upon the baseline heart rate and blood pressure. The dose of beta blocker or calcium channel blocker is titrated as tolerated with the dose limited to avoid hypotension (symptomatic hypotension or asymptomatic systolic blood pressure &lt;100 mmHg) and bradycardia (heart rate &lt;55 beats per minute).</p><p>Among patients who do not respond to optimally titrated <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>, <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>, or beta blockers and who do not want to pursue ablation, the following antiarrhythmic drugs may be considered:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">Flecainide</a> (class IC)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">Propafenone</a> (class IC)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">Sotalol</a> (class III)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">Dofetilide</a> (class III)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> (class III)</p><p></p><p>The choice of a particular agent will need to be individualized in each patient based on other comorbidities. However, due to the potential for significant toxicities, including proarrhythmia, the use of class I and class III antiarrhythmic drugs for the management of AVNRT should be reserved for rare cases and should be administered in consultation with an electrophysiologist. In particular, because of the risk of toxicities with long-term use, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> is usually avoided in young patients. (See  <a class="medical medical_review" href="/z/d/html/931.html" rel="external">"Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"</a>.)</p><p class="headingAnchor" id="H660508885"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116932.html" rel="external">"Society guideline links: Catheter ablation of arrhythmias"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116931.html" rel="external">"Society guideline links: Supraventricular arrhythmias"</a>.)</p><p class="headingAnchor" id="H289851767"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/86463.html" rel="external">"Patient education: Supraventricular tachycardia (SVT) (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H31"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and prevalence</strong> – Atrioventricular nodal reentrant tachycardia (AVNRT) is a regular tachycardia that results from the formation of a reentry circuit confined to the AV node and perinodal atrial tissue. The physiologic substrate for AVNRT involves dual electrical pathways in or near the AV node. It is the most common form of regular, sustained, paroxysmal supraventricular tachycardia (PSVT), and it accounts for nearly two-thirds of all PSVTs. (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – The simplest concept of AV nodal physiology that allows for reentry involves separate electrical pathways within or proximal to the AV node  (<a class="graphic graphic_figure graphicRef79760" href="/z/d/graphic/79760.html" rel="external">figure 3</a>). The fast pathway conducts rapidly and has a relatively long refractory period, while the slow pathway conducts relatively slowly and has a shorter refractory period. Both typical and atypical forms of AVNRT can result from reentry involving the fast and slow pathways. Tachycardia is initiated by a premature beat. (See <a class="local">'Anatomy and pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms</strong> – Patients with AVNRT most commonly report palpitations, dizziness or lightheadedness, and dyspnea. Because of the paroxysmal nature of the arrhythmia, the onset and termination of the symptoms are usually sudden. Those with significant heart disease may have additional symptoms such as dyspnea and chest pain. (See <a class="local">'Symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ECG features</strong> – There are several features seen on an ECG that are helpful in confirming the diagnosis of AVNRT, including the ventricular rate, abrupt onset following a PAC, the relationship between QRS complexes and P waves, and spontaneous termination with AV block in the absence of a PAC. (See <a class="local">'Electrocardiographic characteristics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management</strong> – The initial management  (<a class="graphic graphic_algorithm graphicRef126471" href="/z/d/graphic/126471.html" rel="external">algorithm 1</a>) of a patient presenting with a narrow QRS tachycardia and suspected AVNRT is guided by whether or not the patient is experiencing signs and symptoms of hemodynamic instability related to the rapid heart rate (eg, hypotension, shortness of breath, chest pain suggestive of coronary ischemia, shock, and/or decreased level of consciousness).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemodynamically unstable</strong> – Rare patients who are severely hemodynamically unstable should undergo urgent cardioversion. (See <a class="local">'Electrical cardioversion'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemodynamically stable</strong> – For patients who are hemodynamically stable and able to effectively perform the vagal maneuvers, we recommend at least one or two attempts of a standard Valsalva maneuver, followed by at least one or two attempts using the modified Valsalva maneuver (if AVNRT persists), as the initial treatment for AVNRT rather than another vagal maneuver or <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Vagal maneuvers'</a> above.)</p><p></p><p class="bulletIndent2">If vagal maneuvers cannot be performed or if they fail to terminate the arrhythmia, intravenous (IV) medical therapy that blocks AV nodal conduction is indicated as the next step. For patients with AVNRT that persists following vagal maneuvers (or in whom vagal maneuvers cannot be adequately performed), we recommend IV <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a>  (<a class="graphic graphic_algorithm graphicRef141417" href="/z/d/graphic/141417.html" rel="external">algorithm 3</a>) rather than a calcium channel blocker or a beta blocker (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Adenosine'</a> above.)</p><p></p><p class="bulletIndent2">If both vagal maneuvers and <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> are ineffective, or when these options are followed by an immediate recurrence of the tachycardia, IV <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>, <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>, or a beta blocker can be used to terminate or prevent recurrent AVNRT. (See <a class="local">'Other AV nodal blocking drugs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of recurrent episodes</strong> – The approach to the management of subsequent AVNRT episodes is based around acute management of recurrent episodes and/or preventive therapy to reduce or eliminate recurrences. Because AVNRT is usually well-tolerated in the majority of patients, with a variety of safe and effective treatment options, and there are no compelling data favoring one therapy over another, the choice of long-term management strategies is largely influenced by patient preference.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial management</strong> – For the initial management of recurrent AVNRT, we generally work with the patient to develop a patient-directed treatment approach using either vagal maneuvers or an oral medication ("pill-in-the-pocket" approach). For most patients, we suggest a combination of one or more vagal maneuvers rather than the pill-in-the-pocket approach (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Acute management of recurrent episodes'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infrequent and well-tolerated episodes</strong> – Patients with infrequent and well-tolerated episodes of AVNRT may choose no chronic therapy. For these patients, we emphasize the patient-directed approach to the termination of recurrent episodes using one or more vagal maneuvers. (See <a class="local">'No treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Frequent or poorly tolerated episodes</strong> – For patients with episodes of AVNRT that are either frequently occurring or poorly tolerated (eg, associated with near-syncope or syncope, angina, or severe dyspnea), we recommend catheter ablation rather than chronic medical therapy as initial long-term management strategy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). In such cases, the risks associated with recurrent arrhythmic events (eg, syncope with associated trauma) outweigh the procedural risks. In addition, the potential for definitive therapy makes ablation preferable to medical therapy in this setting. (See <a class="local">'Catheter ablation'</a> above.)</p><p></p><p class="bulletIndent2">For patients with poorly tolerated symptomatic episodes of AVNRT who are not candidates for or who have declined catheter ablation, chronic medical therapy using beta blockers, nondihydropyridine calcium channel blockers, or antiarrhythmic drugs can be initiated in an effort to suppress recurrent arrhythmias. Our experts typical prefer beta blockers rather than calcium channel blockers or antiarrhythmic drugs as the initial option for chronic medical therapy. (See <a class="local">'Chronic suppressive therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Liuba I, Jönsson A, Säfström K, Walfridsson H. Gender-related differences in patients with atrioventricular nodal reentry tachycardia. Am J Cardiol 2006; 97:384.</a></li><li><a class="nounderline abstract_t">Ferguson JD, DiMarco JP. Contemporary management of paroxysmal supraventricular tachycardia. Circulation 2003; 107:1096.</a></li><li><a class="nounderline abstract_t">Ganz LI, Friedman PL. Supraventricular tachycardia. N Engl J Med 1995; 332:162.</a></li><li><a class="nounderline abstract_t">Goyal R, Zivin A, Souza J, et al. Comparison of the ages of tachycardia onset in patients with atrioventricular nodal reentrant tachycardia and accessory pathway-mediated tachycardia. Am Heart J 1996; 132:765.</a></li><li><a class="nounderline abstract_t">McGuire MA, Bourke JP, Robotin MC, et al. High resolution mapping of Koch's triangle using sixty electrodes in humans with atrioventricular junctional (AV nodal) reentrant tachycardia. Circulation 1993; 88:2315.</a></li><li><a class="nounderline abstract_t">McGuire MA, Janse MJ, Ross DL. "AV nodal" reentry: Part II: AV nodal, AV junctional, or atrionodal reentry? J Cardiovasc Electrophysiol 1993; 4:573.</a></li><li><a class="nounderline abstract_t">Meiltz A, Zimmermann M. Atrioventricular nodal reentrant tachycardia in the elderly: efficacy and safety of radiofrequency catheter ablation. Pacing Clin Electrophysiol 2007; 30 Suppl 1:S103.</a></li><li><a class="nounderline abstract_t">Grecu M, Floria M, Georgescu CA. Abnormal atrioventricular node conduction and atrioventricular nodal reentrant tachycardia in patients older versus younger than 65 years of age. Pacing Clin Electrophysiol 2009; 32 Suppl 1:S98.</a></li><li><a class="nounderline abstract_t">Janse MJ, Anderson RH, McGuire MA, Ho SY. "AV nodal" reentry: Part I: "AV nodal" reentry revisited. J Cardiovasc Electrophysiol 1993; 4:561.</a></li><li><a class="nounderline abstract_t">Pieper SJ, Stanton MS. Narrow QRS complex tachycardias. Mayo Clin Proc 1995; 70:371.</a></li><li><a class="nounderline abstract_t">Yamabe H, Shimasaki Y, Honda O, et al. Demonstration of the exact anatomic tachycardia circuit in the fast-slow form of atrioventricular nodal reentrant tachycardia. Circulation 2001; 104:1268.</a></li><li><a class="nounderline abstract_t">Mazgalev TN, Tchou PJ. Surface potentials from the region of the atrioventricular node and their relation to dual pathway electrophysiology. Circulation 2000; 101:2110.</a></li><li><a class="nounderline abstract_t">Sung RJ, Waxman HL, Saksena S, Juma Z. Sequence of retrograde atrial activation in patients with dual atrioventricular nodal pathways. Circulation 1981; 64:1059.</a></li><li><a class="nounderline abstract_t">Hayes JJ, Sharma PP, Smith PN, Vidaillet HJ. Familial atrioventricular nodal reentry tachycardia. Pacing Clin Electrophysiol 2004; 27:73.</a></li><li><a class="nounderline abstract_t">MOE GK, PRESTON JB, BURLINGTON H. Physiologic evidence for a dual A-V transmission system. Circ Res 1956; 4:357.</a></li><li><a class="nounderline abstract_t">Man KC, Brinkman K, Bogun F, et al. 2:1 atrioventricular block during atrioventricular node reentrant tachycardia. J Am Coll Cardiol 1996; 28:1770.</a></li><li><a class="nounderline abstract_t">Schmitt C, Miller JM, Josephson ME. Atrioventricular nodal supraventricular tachycardia with 2:1 block above the bundle of His. Pacing Clin Electrophysiol 1988; 11:1018.</a></li><li><a class="nounderline abstract_t">Yeh SJ, Yamamoto T, Lin FC, Wu D. Atrioventricular block in the atypical form of junctional reciprocating tachycardia: evidence supporting the atrioventricular node as the site of reentry. J Am Coll Cardiol 1990; 15:385.</a></li><li><a class="nounderline abstract_t">Bogun F, Daoud E, Goyal R, et al. Comparison of atrial-His intervals in patients with and without dual atrioventricular nodal physiology and atrioventricular nodal reentrant tachycardia. Am Heart J 1996; 132:758.</a></li><li><a class="nounderline abstract_t">Otomo K, Suyama K, Okamura H, et al. Participation of a concealed atriohisian tract in the reentrant circuit of the slow-fast type of atrioventricular nodal reentrant tachycardia. Heart Rhythm 2007; 4:703.</a></li><li><a class="nounderline abstract_t">Wu J, Zipes DP. Mechanisms underlying atrioventricular nodal conduction and the reentrant circuit of atrioventricular nodal reentrant tachycardia using optical mapping. J Cardiovasc Electrophysiol 2002; 13:831.</a></li><li><a class="nounderline abstract_t">Kwaku KF, Josephson ME. Typical AVNRT--an update on mechanisms and therapy. Card Electrophysiol Rev 2002; 6:414.</a></li><li><a class="nounderline abstract_t">Hale ZD, Greet BD, Burkland DA, et al. Slow-pathway visualization by using voltage-time relationship: A novel technique for identification and fluoroless ablation of atrioventricular nodal reentrant tachycardia. J Cardiovasc Electrophysiol 2020; 31:1430.</a></li><li><a class="nounderline abstract_t">Otomo K, Nagata Y, Uno K, et al. Atypical atrioventricular nodal reentrant tachycardia with eccentric coronary sinus activation: electrophysiological characteristics and essential effects of left-sided ablation inside the coronary sinus. Heart Rhythm 2007; 4:421.</a></li><li><a class="nounderline abstract_t">Katritsis DG, Marine JE, Latchamsetty R, et al. Coexistent Types of Atrioventricular Nodal Re-Entrant Tachycardia: Implications for the Tachycardia Circuit. Circ Arrhythm Electrophysiol 2015; 8:1189.</a></li><li><a class="nounderline abstract_t">Abe H, Nagatomo T, Kobayashi H, et al. Neurohumoral and hemodynamic mechanisms of diuresis during atrioventricular nodal reentrant tachycardia. Pacing Clin Electrophysiol 1997; 20:2783.</a></li><li><a class="nounderline abstract_t">Wood KA, Drew BJ, Scheinman MM. Frequency of disabling symptoms in supraventricular tachycardia. Am J Cardiol 1997; 79:145.</a></li><li><a class="nounderline abstract_t">Doi A, Miyamoto K, Uno K, et al. Studies on hemodynamic instability in paroxysmal supraventricular tachycardia: noninvasive evaluations by head-up tilt testing and power spectrum analysis on electrocardiographic RR variation. Pacing Clin Electrophysiol 2000; 23:1623.</a></li><li><a class="nounderline abstract_t">Leitch JW, Klein GJ, Yee R, et al. Syncope associated with supraventricular tachycardia. An expression of tachycardia rate or vasomotor response? Circulation 1992; 85:1064.</a></li><li><a class="nounderline abstract_t">Wang YS, Scheinman MM, Chien WW, et al. Patients with supraventricular tachycardia presenting with aborted sudden death: incidence, mechanism and long-term follow-up. J Am Coll Cardiol 1991; 18:1711.</a></li><li><a class="nounderline abstract_t">Tisdale JE, Chung MK, Campbell KB, et al. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation 2020; 142:e214.</a></li><li><a class="nounderline abstract_t">Chiou CW, Chen SA, Kung MH, et al. Effects of continuous enhanced vagal tone on dual atrioventricular node and accessory pathways. Circulation 2003; 107:2583.</a></li><li><a class="nounderline abstract_t">Ng KS, Lauer MR, Young C, et al. Correlation of P-wave polarity with underlying electrophysiologic mechanisms of long RP' tachycardia. Am J Cardiol 1996; 77:1129.</a></li><li><a class="nounderline abstract_t">Riva SI, Della Bella P, Fassini G, et al. Value of analysis of ST segment changes during tachycardia in determining type of narrow QRS complex tachycardia. J Am Coll Cardiol 1996; 27:1480.</a></li><li><a class="nounderline abstract_t">Güleç S, Ertaş F, Karaoŏuz R, et al. Value of ST-segment depression during paroxysmal supraventricular tachycardia in the diagnosis of coronary artery disease. Am J Cardiol 1999; 83:458.</a></li><li><a class="nounderline abstract_t">Imrie JR, Yee R, Klein GJ, Sharma AD. Incidence and clinical significance of ST segment depression in supraventricular tachycardia. Can J Cardiol 1990; 6:323.</a></li><li><a class="nounderline abstract_t">Petsas AA, Anastassiades LC, Antonopoulos AG. Exercise testing for assessment of the significance of ST segment depression observed during episodes of paroxysmal supraventricular tachycardia. Eur Heart J 1990; 11:974.</a></li><li><a class="nounderline abstract_t">Paparella N, Ouyang F, Fucă G, et al. Significance of newly acquired negative T waves after interruption of paroxysmal reentrant supraventricular tachycardia with narrow QRS complex. Am J Cardiol 2000; 85:261.</a></li><li><a class="nounderline abstract_t">Villain E, Vetter VL, Garcia JM, et al. Evolving concepts in the management of congenital junctional ectopic tachycardia. A multicenter study. Circulation 1990; 81:1544.</a></li><li><a class="nounderline abstract_t">Fishberger SB, Rossi AF, Messina JJ, Saul JP. Successful radiofrequency catheter ablation of congenital junctional ectopic tachycardia with preservation of atrioventricular conduction in a 9-month-old infant. Pacing Clin Electrophysiol 1998; 21:2132.</a></li><li><a class="nounderline abstract_t">Wang NC. Dual atrioventricular nodal nonreentrant tachycardia: a systematic review. Pacing Clin Electrophysiol 2011; 34:1671.</a></li><li><a class="nounderline abstract_t">Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2016; 133:e506.</a></li><li><a class="nounderline abstract_t">Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020; 41:655.</a></li><li><a class="nounderline abstract_t">Belz MK, Stambler BS, Wood MA, et al. Effects of enhanced parasympathetic tone on atrioventricular nodal conduction during atrioventricular nodal reentrant tachycardia. Am J Cardiol 1997; 80:878.</a></li><li><a class="nounderline abstract_t">Pandya A, Lang E. Valsalva maneuver for termination of supraventricular tachycardia. Ann Emerg Med 2015; 65:27.</a></li><li><a class="nounderline abstract_t">Appelboam A, Reuben A, Mann C, et al. Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial. Lancet 2015; 386:1747.</a></li><li><a class="nounderline abstract_t">Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation 1999; 99:1034.</a></li><li><a class="nounderline abstract_t">Cairns CB, Niemann JT. Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachycardia. Ann Emerg Med 1991; 20:717.</a></li><li><a class="nounderline abstract_t">Rankin AC, Brooks R, Ruskin JN, McGovern BA. Adenosine and the treatment of supraventricular tachycardia. Am J Med 1992; 92:655.</a></li><li><a class="nounderline abstract_t">Waxman HL, Myerburg RJ, Appel R, Sung RJ. Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study. Ann Intern Med 1981; 94:1.</a></li><li><a class="nounderline abstract_t">Das G, Tschida V, Gray R, et al. Efficacy of esmolol in the treatment and transfer of patients with supraventricular tachyarrhythmias to alternate oral antiarrhythmic agents. J Clin Pharmacol 1988; 28:746.</a></li><li><a class="nounderline abstract_t">Stambler BS, Dorian P, Sager PT, et al. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol 2018; 72:489.</a></li><li><a class="nounderline abstract_t">Abuelazm M, Kambalapalli S, Saleh O, et al. The Efficacy and Safety of Etripamil Nasal Spray for Acute Paroxysmal Supraventricular Tachycardia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Cardiovasc Drugs 2023; 23:379.</a></li><li><a class="nounderline abstract_t">Sung RJ, Elser B, McAllister RG Jr. Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations. Ann Intern Med 1980; 93:682.</a></li><li><a class="nounderline abstract_t">DiMarco JP, Sellers TD, Berne RM, et al. Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation 1983; 68:1254.</a></li><li><a class="nounderline abstract_t">Dougherty AH, Jackman WM, Naccarelli GV, et al. Acute conversion of paroxysmal supraventricular tachycardia with intravenous diltiazem. IV Diltiazem Study Group. Am J Cardiol 1992; 70:587.</a></li><li><a class="nounderline abstract_t">Margolis B, DeSilva RA, Lown B. Episodic drug treatment in the management of paroxysmal arrhythmias. Am J Cardiol 1980; 45:621.</a></li><li><a class="nounderline abstract_t">Alboni P, Tomasi C, Menozzi C, et al. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol 2001; 37:548.</a></li><li><a class="nounderline abstract_t">Spector P, Reynolds MR, Calkins H, et al. Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. Am J Cardiol 2009; 104:671.</a></li><li><a class="nounderline abstract_t">Chrispin J, Misra S, Marine JE, et al. Current management and clinical outcomes for catheter ablation of atrioventricular nodal re-entrant tachycardia. Europace 2018; 20:e51.</a></li><li><a class="nounderline abstract_t">Katritsis DG, Marine JE, Contreras FM, et al. Catheter Ablation of Atypical Atrioventricular Nodal Reentrant Tachycardia. Circulation 2016; 134:1655.</a></li><li><a class="nounderline abstract_t">Hosseini SM, Rozen G, Saleh A, et al. Catheter ablation for cardiac arrhythmias: utilization and in-hospital complications, 2000 to 2013. J Am Coll Cardiol EP 2017; 3:1240.</a></li><li><a class="nounderline abstract_t">Katritsis DG, Zografos T, Siontis KC, et al. Endpoints for Successful Slow Pathway Catheter Ablation in Typical and Atypical Atrioventricular Nodal Re-Entrant Tachycardia: A Contemporary, Multicenter Study. J Am Coll Cardiol EP 2019; 5:113.</a></li><li><a class="nounderline abstract_t">Boulos M, Hoch D, Schecter S, et al. Age dependence of complete heart block complicating radiofrequency ablation of the atrioventricular nodal slow pathway. Am J Cardiol 1998; 82:390.</a></li><li><a class="nounderline abstract_t">Li YG, Grönefeld G, Bender B, et al. Risk of development of delayed atrioventricular block after slow pathway modification in patients with atrioventricular nodal reentrant tachycardia and a pre-existing prolonged PR interval. Eur Heart J 2001; 22:89.</a></li><li><a class="nounderline abstract_t">Natale A, Greenfield RA, Geiger MJ, et al. Safety of slow pathway ablation in patients with long PR interval: further evidence of fast and slow pathway interaction. Pacing Clin Electrophysiol 1997; 20:1698.</a></li><li><a class="nounderline abstract_t">Reithmann C, Hoffmann E, Grünewald A, et al. Fast pathway ablation in patients with common atrioventricular nodal reentrant tachycardia and prolonged PR interval during sinus rhythm. Eur Heart J 1998; 19:929.</a></li><li><a class="nounderline abstract_t">Kaneko Y, Naito S, Okishige K, et al. Atypical Fast-Slow Atrioventricular Nodal Reentrant Tachycardia Incorporating a "Superior" Slow Pathway: A Distinct Supraventricular Tachyarrhythmia. Circulation 2016; 133:114.</a></li><li><a class="nounderline abstract_t">Katritsis DG, John RM, Latchamsetty R, et al. Left Septal Slow Pathway Ablation for Atrioventricular Nodal Reentrant Tachycardia. Circ Arrhythm Electrophysiol 2018; 11:e005907.</a></li><li><a class="nounderline abstract_t">Bathina MN, Mickelsen S, Brooks C, et al. Radiofrequency catheter ablation versus medical therapy for initial treatment of supraventricular tachycardia and its impact on quality of life and healthcare costs. Am J Cardiol 1998; 82:589.</a></li></ol></div><div id="topicVersionRevision">Topic 902 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16442401" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Gender-related differences in patients with atrioventricular nodal reentry tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12615783" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Contemporary management of paroxysmal supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7800009" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8831363" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparison of the ages of tachycardia onset in patients with atrioventricular nodal reentrant tachycardia and accessory pathway-mediated tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8222125" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : High resolution mapping of Koch's triangle using sixty electrodes in humans with atrioventricular junctional (AV nodal) reentrant tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8269323" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : "AV nodal" reentry: Part II: AV nodal, AV junctional, or atrionodal reentry?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17302682" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Atrioventricular nodal reentrant tachycardia in the elderly: efficacy and safety of radiofrequency catheter ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19250123" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Abnormal atrioventricular node conduction and atrioventricular nodal reentrant tachycardia in patients older versus younger than 65 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8269322" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : "AV nodal" reentry: Part I: "AV nodal" reentry revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7898144" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Narrow QRS complex tachycardias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11551878" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Demonstration of the exact anatomic tachycardia circuit in the fast-slow form of atrioventricular nodal reentrant tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10790355" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Surface potentials from the region of the atrioventricular node and their relation to dual pathway electrophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7285296" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Sequence of retrograde atrial activation in patients with dual atrioventricular nodal pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14720158" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Familial atrioventricular nodal reentry tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13330177" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Physiologic evidence for a dual A-V transmission system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8962565" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : 2:1 atrioventricular block during atrioventricular node reentrant tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2457879" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Atrioventricular nodal supraventricular tachycardia with 2:1 block above the bundle of His.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2299081" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Atrioventricular block in the atypical form of junctional reciprocating tachycardia: evidence supporting the atrioventricular node as the site of reentry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8831362" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparison of atrial-His intervals in patients with and without dual atrioventricular nodal physiology and atrioventricular nodal reentrant tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17556188" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Participation of a concealed atriohisian tract in the reentrant circuit of the slow-fast type of atrioventricular nodal reentrant tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12212708" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Mechanisms underlying atrioventricular nodal conduction and the reentrant circuit of atrioventricular nodal reentrant tachycardia using optical mapping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12438822" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Typical AVNRT--an update on mechanisms and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32270564" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Slow-pathway visualization by using voltage-time relationship: A novel technique for identification and fluoroless ablation of atrioventricular nodal reentrant tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17399627" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Atypical atrioventricular nodal reentrant tachycardia with eccentric coronary sinus activation: electrophysiological characteristics and essential effects of left-sided ablation inside the coronary sinus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26155802" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Coexistent Types of Atrioventricular Nodal Re-Entrant Tachycardia: Implications for the Tachycardia Circuit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9392809" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Neurohumoral and hemodynamic mechanisms of diuresis during atrioventricular nodal reentrant tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9193013" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Frequency of disabling symptoms in supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11138299" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Studies on hemodynamic instability in paroxysmal supraventricular tachycardia: noninvasive evaluations by head-up tilt testing and power spectrum analysis on electrocardiographic RR variation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1537103" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Syncope associated with supraventricular tachycardia. An expression of tachycardia rate or vasomotor response?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1960318" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Patients with supraventricular tachycardia presenting with aborted sudden death: incidence, mechanism and long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32929996" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12743004" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of continuous enhanced vagal tone on dual atrioventricular node and accessory pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8644674" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Correlation of P-wave polarity with underlying electrophysiologic mechanisms of long RP' tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8626962" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Value of analysis of ST segment changes during tachycardia in determining type of narrow QRS complex tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10072244" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Value of ST-segment depression during paroxysmal supraventricular tachycardia in the diagnosis of coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2268794" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Incidence and clinical significance of ST segment depression in supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2282927" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Exercise testing for assessment of the significance of ST segment depression observed during episodes of paroxysmal supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10955389" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Significance of newly acquired negative T waves after interruption of paroxysmal reentrant supraventricular tachycardia with narrow QRS complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2184944" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Evolving concepts in the management of congenital junctional ectopic tachycardia. A multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9826867" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Successful radiofrequency catheter ablation of congenital junctional ectopic tachycardia with preservation of atrioventricular conduction in a 9-month-old infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21950798" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Dual atrioventricular nodal nonreentrant tachycardia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26399663" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504425" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9382001" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effects of enhanced parasympathetic tone on atrioventricular nodal conduction during atrioventricular nodal reentrant tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23932719" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Valsalva maneuver for termination of supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26314489" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10051297" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Electrophysiologic effects of adenosine in patients with supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2064090" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Intravenous adenosine in the emergency department management of paroxysmal supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1605147" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Adenosine and the treatment of supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7447203" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2905710" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Efficacy of esmolol in the treatment and transfer of patients with supraventricular tachyarrhythmias to alternate oral antiarrhythmic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30049309" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37351813" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The Efficacy and Safety of Etripamil Nasal Spray for Acute Paroxysmal Supraventricular Tachycardia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7212475" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6640877" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1510006" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Acute conversion of paroxysmal supraventricular tachycardia with intravenous diltiazem. IV Diltiazem Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7355758" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Episodic drug treatment in the management of paroxysmal arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11216977" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19699343" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Meta-analysis of ablation of atrial flutter and supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28541507" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Current management and clinical outcomes for catheter ablation of atrioventricular nodal re-entrant tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27754882" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Catheter Ablation of Atypical Atrioventricular Nodal Reentrant Tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Catheter ablation for cardiac arrhythmias: utilization and in-hospital complications, 2000 to 2013</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Endpoints for Successful Slow Pathway Catheter Ablation in Typical and Atypical Atrioventricular Nodal Re-Entrant Tachycardia: A Contemporary, Multicenter Study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9708674" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Age dependence of complete heart block complicating radiofrequency ablation of the atrioventricular nodal slow pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11133214" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Risk of development of delayed atrioventricular block after slow pathway modification in patients with atrioventricular nodal reentrant tachycardia and a pre-existing prolonged PR interval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9227770" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Safety of slow pathway ablation in patients with long PR interval: further evidence of fast and slow pathway interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9651718" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fast pathway ablation in patients with common atrioventricular nodal reentrant tachycardia and prolonged PR interval during sinus rhythm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26541829" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Atypical Fast-Slow Atrioventricular Nodal Reentrant Tachycardia Incorporating a "Superior" Slow Pathway: A Distinct Supraventricular Tachyarrhythmia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29540373" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Left Septal Slow Pathway Ablation for Atrioventricular Nodal Reentrant Tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9732885" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Radiofrequency catheter ablation versus medical therapy for initial treatment of supraventricular tachycardia and its impact on quality of life and healthcare costs.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
